Mon, March 26, 2012
Sun, March 25, 2012
Sat, March 24, 2012
Fri, March 23, 2012
Thu, March 22, 2012
Wed, March 21, 2012
Tue, March 20, 2012
Mon, March 19, 2012
Sun, March 18, 2012
Fri, March 16, 2012
Thu, March 15, 2012
Wed, March 14, 2012
Tue, March 13, 2012
Mon, March 12, 2012

Stellar to Hold Conference Call re Health Canada Approval of CAMBIA(R) for the Treatment of Acute Migraines


//health-fitness.news-articles.net/content/2012/ .. mbia-r-for-the-treatment-of-acute-migraines.html
Published in Health and Fitness on Monday, March 19th 2012 at 5:37 GMT by Market Wire   Print publication without navigation


March 19, 2012 08:30 ET

Stellar to Hold Conference Call re Health Canada Approval of CAMBIA® for the Treatment of Acute Migraines

MILTON, ONTARIO--(Marketwire - March 19, 2012) - Stellar Pharmaceuticals Inc. ("Stellar") (OTCQB:SLXCF)(OTCBB:SLXCF)(PINKSHEETS:SLXCF), a Canadian public company, announced today that the Company intends host a conference call at 4:00 p.m. Eastern Time on Monday, March 19, 2012 to discuss the details of the approval of CAMBIA®, (diclofenac potassium for oral solution) for the treatment of migraine attacks with or without aura in adults, by Health Canada as noted in the press release dated Friday, March 16, 2012. The dial-in number to access the call is US/Canada 866-223-7781, International 416-340-8018.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on March 26, 2012. The replay may be accessed by dialing 800-408-30853 and entering Pass code 5515831. From international locations, the replay may be accessed by dialing 905-694-9451. To access the webcast, go to Stellar Web site at [ http://stellarpharma.com ]. A replay of the webcast will also be available.

About Stellar Pharmaceuticals Inc.

Stellar and its subsidiary, Tribute Pharmaceuticals, is an emerging Canadian specialty pharmaceutical company focused on the acquisition, licensing, development and management of pharmaceutical and healthcare products with its primary focus on the Canadian market.

Stellar markets Bezalip®* SR (bezafibrate), NeoVisc® (1.0% sodium hyaluronate solution), Soriatane®* (acitretin) and Uracyst® (sodium chondroitin sulfate solution 2%) in the Canadian market place. NeoVisc® and Uracyst® are sold globally through various international partnerships. Additionally, Stellar is currently in negotiations to license both NeoVisc® and Uracyst® in the US and other international markets.

For further information on Stellar Pharma, visit [ http://www.stellarpharma.com ] and for information on its subsidiary please visit [ http://www.tributepharma.com ].

*Soriatane and Bezalip are registered trademarks and under license from Actavis Group PTC ehf
**Cambia is a registered trademark and under license from Nautilus Neurosciences, Inc.



Publication Contributing Sources